MARPLAN
LOE Approachingisocarboxazid
NDAORALTABLET
Approved
Jul 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARPLAN (isocarboxazid) is an oral monoamine oxidase inhibitor (MAOI) approved in 1959 for the treatment of depression and anxiety disorders. It works by inhibiting monoamine oxidase enzyme, thereby increasing levels of serotonin, norepinephrine, and dopamine in the central nervous system. This vintage antidepressant remains in use despite being largely displaced by newer agents due to efficacy in treatment-resistant cases.
$0.349MPart D
LOE ApproachingMinimal commercial footprint with 417 annual claims signals a niche product with small team requirements and limited growth potential for brand-building roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MARPLAN offers minimal career growth potential given near-zero job pipeline and LOE-approaching lifecycle status. This role suits candidates seeking stable, low-pressure positions in niche psychiatry or those building end-of-life product management experience before transition opportunities.
Brand Manager (defensive/maintenance)Sales Representative (specialty/psychiatry focus)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.